175 related articles for article (PubMed ID: 21837778)
1. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
Dalrymple SL; Becker RE; Zhou H; DeWeese TL; Isaacs JT
Prostate; 2012 May; 72(6):638-48. PubMed ID: 21837778
[TBL] [Abstract][Full Text] [Related]
2. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
3. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.
Isaacs JT
Expert Opin Investig Drugs; 2010 Oct; 19(10):1235-43. PubMed ID: 20836618
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
6. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
[TBL] [Abstract][Full Text] [Related]
7. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
8. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
George S; Pili R
Curr Oncol Rep; 2013 Apr; 15(2):65-8. PubMed ID: 23334511
[TBL] [Abstract][Full Text] [Related]
9. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
10. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Shen L; Sundstedt A; Ciesielski M; Miles KM; Celander M; Adelaiye R; Orillion A; Ciamporcero E; Ramakrishnan S; Ellis L; Fenstermaker R; Abrams SI; Eriksson H; Leanderson T; Olsson A; Pili R
Cancer Immunol Res; 2015 Feb; 3(2):136-48. PubMed ID: 25370534
[TBL] [Abstract][Full Text] [Related]
11. A review of tasquinimod in the treatment of advanced prostate cancer.
Williamson SC; Hartley AE; Heer R
Drug Des Devel Ther; 2013; 7():167-74. PubMed ID: 23662046
[TBL] [Abstract][Full Text] [Related]
12. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
Bratt O; Häggman M; Ahlgren G; Nordle O; Björk A; Damber JE
Br J Cancer; 2009 Oct; 101(8):1233-40. PubMed ID: 19755981
[TBL] [Abstract][Full Text] [Related]
13. Tasquinimod: a novel drug in advanced prostate cancer.
Osanto S; van Poppel H; Burggraaf J
Future Oncol; 2013 Sep; 9(9):1271-81. PubMed ID: 23980674
[TBL] [Abstract][Full Text] [Related]
14. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.
Xu L; Yang D; Wang S; Tang W; Liu M; Davis M; Chen J; Rae JM; Lawrence T; Lippman ME
Mol Cancer Ther; 2005 Feb; 4(2):197-205. PubMed ID: 15713891
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
[TBL] [Abstract][Full Text] [Related]
16. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
[TBL] [Abstract][Full Text] [Related]
17. [Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
Houédé N; Irani J
Prog Urol; 2015 May; 25(6):298-305. PubMed ID: 25684391
[TBL] [Abstract][Full Text] [Related]
18. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Isaacs JT; Antony L; Dalrymple SL; Brennen WN; Gerber S; Hammers H; Wissing M; Kachhap S; Luo J; Xing L; Björk P; Olsson A; Björk A; Leanderson T
Cancer Res; 2013 Feb; 73(4):1386-99. PubMed ID: 23149916
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.
Røe K; Seierstad T; Kristian A; Mikalsen LT; Mælandsmo GM; van der Kogel AJ; Ree AH; Olsen DR
Neoplasia; 2010 Oct; 12(10):818-25. PubMed ID: 20927320
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
